Physician profile
John R Fuller
NPI 1801817267
$917.90
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $352 · 2021: $247 · 2022: $45.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $279.04 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $138.32 | 2019-2021 | |
| Janssen Biotech, INC. | $124.43 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $71.80 | 2020-2022 | |
| Abbvie INC. | $53.53 | 2020-2021 | |
| Allergan, INC. | $49.28 | 2019-2021 | |
| Myovant Sciences INC. | $38.88 | 2021 | |
| Pfizer INC. | $31.31 | 2019 | |
| Merck Sharp & Dohme LLC | $26.58 | 2020-2021 | |
| Laborie Medical Technologies Corp. | $18.80 | 2020 | |
| 180 Medical, INC. | $18.05 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $15.78 | 2021 | |
| Boston Scientific Corporation | $15.38 | 2019 | |
| Neotract INC. | $13.19 | 2020 | |
| Axonics, INC. | $11.97 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $11.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.